Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ARTEMIS-002: A Phase 2, Multicenter, Open-label Study of Intravenous Administration of HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas

NCT05830123 is registered in ClinicalTrials.gov with Hansoh BioMedical R&D Company as lead sponsor.

NCT NCT05830123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05830123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ARTEMIS-002: A Phase 2, Multicenter, Open-label Study of Intravenous Administration of HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
Lead sponsor
Hansoh BioMedical R&D Company
Phase
Phase 2
Overall status
Recruiting
Start date
June 8, 2023
Completion date
December 31, 2027
Enrollment
170 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

osteosarcoma, sarcoma